{"filing":{"accession_number":"0001213900-26-074040","cik":"0001783036","ticker":"NCEL","company_name":"NewcelX Ltd.","form":"6-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ea0296667-6k_newcelx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783036/000121390026074040/ea0296667-6k_newcelx.htm"},"events":[{"id":15378,"run_id":13721,"accession_number":"0001213900-26-074040","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"NewcelX announced successful completion of a Type B Pre-IND meeting with the FDA, receiving constructive feedback and regulatory alignment on its development strategy for NCEL-101 in combination with tegoprubart for type 1 diabetes. This is a material regulatory milestone that clears the path toward IND-enabling activities and clinical trial initiation, representing significant progress in the company's lead program development. While not a discrete transaction (M\u0026A), financial event, or governance matter, this regulatory achievement is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory.","company_name":"NewcelX Ltd.","ticker":"NCEL","filing_date":"2026-07-01","form":"6-K","submitted_at":null,"items":[{"id":13124,"accession_number":"0001213900-26-074040","item_number":"EX-99.1","item_title":"ea029666701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NewcelX announced successful completion of a Type B Pre-IND meeting with the FDA, receiving constructive feedback and regulatory alignment on its development strategy for NCEL-101 in combination with tegoprubart for type 1 diabetes. This is a material regulatory milestone that clears the path toward IND-enabling activities and clinical trial initiation, representing significant progress in the company's lead program development. While not a discrete transaction (M\u0026A), financial event, or governance matter, this regulatory achievement is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T13:31:38.986483+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13124,"accession_number":"0001213900-26-074040","item_number":"EX-99.1","item_title":"ea029666701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NewcelX announced successful completion of a Type B Pre-IND meeting with the FDA, receiving constructive feedback and regulatory alignment on its development strategy for NCEL-101 in combination with tegoprubart for type 1 diabetes. This is a material regulatory milestone that clears the path toward IND-enabling activities and clinical trial initiation, representing significant progress in the company's lead program development. While not a discrete transaction (M\u0026A), financial event, or governance matter, this regulatory achievement is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's clinical development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T13:31:38.986483+00:00","company_name":"NewcelX Ltd.","ticker":"NCEL","filing_date":"2026-07-01"}]}